GSK delivered its Q2 results on July 29 and the post-print picture looks materially different from the cautious setup that preceded it.
The most striking data shift this week is the ORTEX short score, which collapsed from 37.1 on July 27 to 26.2 by July 30 — a ten-point drop in three sessions. That move puts the score firmly in the lower third of the scale and signals that the short-side conviction that had been building into the earnings event dissolved quickly once the numbers were out. The score ranks in the 94th percentile for low short pressure across the universe, meaning very few large-cap names carry less short-side stress right now. That is a meaningful change from the pre-earnings posture described in last week's notes.
The lending market reinforces that read. Borrow availability remains exceptionally loose — with over 1.6 billion shares available to borrow and availability running at the ceiling of the data range, this is one of the least squeezed large-cap names in European pharma. Cost to borrow has eased back to 0.52%, down from a brief spike to 0.61% earlier in the week, and is roughly 9% cheaper than a month ago. There is no sign of any meaningful short rebuild in the aftermath of the results. Taken together, the lending data and the short score drop tell the same story: bears stepped back sharply after the print.
The Street picture is broadly constructive. The analyst consensus mean price target of £21.42 sits about 11% above the current price of £19.32, which closed flat on the week after a brief dip on the day of results. Factor scores add texture — GSK ranks in the 93rd percentile on analyst recommendation divergence, suggesting the Street is more bullish than the stock's recent price behaviour implies. The dividend score ranks in the 90th percentile. EV/EBITDA has drifted down about 0.3x over 30 days to 7.6x, and the P/E of 10.3x remains undemanding for a business of this quality and scale. The recent notes flagged oncology pipeline progress and stronger-than-expected launch uptake in immuno-oncology as the bull case anchors; Zantac litigation overhang and pipeline execution risk remain the bear case.
On ownership, the top of the register is broadly stable. BlackRock holds 10.25% and added roughly 6.4 million shares in the last reported period. Fidelity (FMR LLC) added more aggressively — over 20 million shares — bringing its stake to 4.8%. Amundi also added 12.4 million shares. Against that, Dodge & Cox trimmed modestly and the GSK Employee Trust reduced by 1.75 million shares. The net direction from institutional holders is gently accumulative, which sits consistently with the constructive analyst positioning.
The post-earnings sell-off of 4.4% on July 29 — visible in the earnings history — stands out against the more muted reactions that followed the other events listed in the same period. The next scheduled print is October 28. Between now and then, the question for holders is whether the oncology pipeline milestones and Q2 launch momentum can hold the stock above the £19 level that has served as a repeated test over the past several months.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
